EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Assessment of drug sensitivity of human leukemic myelo blasts part 1 labeling human myelo blasts with iodine 125 5 iodo 2 deoxy uridine for survival studies in mice



Assessment of drug sensitivity of human leukemic myelo blasts part 1 labeling human myelo blasts with iodine 125 5 iodo 2 deoxy uridine for survival studies in mice



British Journal of Cancer 36(3): 297-306



The compound 125IUdR [[125I] 5-iodo-2'-deoxyuridine] can be incorporated in a stable form into the DNA of cells. The isotope is released if labeled cells or their progeny die. The rate of 125I excretion from mice can be used to follow the fate of labeled cells in vivo. Sufficient label can be incorporated in vitro into fresh and cryopreserved human leukemic myeloblasts, in nontoxic concentrations, to allow their survival in mice to be estimated by whole-body counting. The release of isotope from labeled cells is sufficiently slow to offer reasonable expectation that this technique can be used for assessing the sensitivity of myeloblasts to cytotoxic agents in vivo. The rate of 125I excretion from mice injected with myeloblasts from different donors varies. This probably reflects different rates of spontaneous death of injected myeloblasts. Active rejection of myeloblasts starts within 48 h of injection into mice. Phagocytic cells may be active agents in myeloblast destruction in mice. Various methods of immunologically depriving mice were assessed to see if they would result in a useful increase in survival of injected human myeloblasts. There is little advantage and some limitations in using mice thus deprived. One of the agents used for immunological deprivation, silica powder decreased the rate of 125I loss from mice injected with labeled killed myeloblasts. This experience emphasizes the importance of including the killed cell control in this assay.

(PDF emailed within 1 workday: $29.90)

Accession: 004787054

Download citation: RISBibTeXText



Related references

Assessment of drug sensitivity of human leukemic myelo blasts part 2 the toxic effects of cytosine arabinoside on iodine 125 5 iodo 2 deoxy uridine labeled human leukemic myelo blasts in mice. British Journal of Cancer 36(3): 307-312, 1977

Fowl plague virus adapted to human epithelial tumor cells and human myelo blasts in vitro part 2 replication in human leukemic myelo blast cultures. Archiv fuer die Gesamte Virusforschung 40(3-4): 255-264, 1973

Specificity and sensitivity of cortisol induced changes in alpha amino iso butyric acid transport in human leukemic small lymphocytes and leukemic myelo blasts. Journal of Clinical Investigation 52(6): 1518-1525, 1973

Cyto toxicity against human leukemic cells part 1 demonstration of antibody dependent lymphocyte killing of human allogeneic myelo blasts. Clinical & Experimental Immunology: 159-167, 1973

Morphological phase contrast cinematographic studies on bone marrow cells in vitro part 10 myelo blasts and mono blasts. Blut 32(2): 115-130, 1976

Nuclear dna polymerase estimation in human leukemic myelo blasts. British Journal of Haematology 33(3): 329-334, 1976

Kinetic pattern of human leukemic myelo blasts after cytosine arabinoside injection. Acta Haematologica (Basel) 49(1): 6-14, 1973

Serological detection of bone marrow derived cell ia immune response associated antigens on human leukemic myelo blasts. Clinical Research 25(5): 693A, 1977

Surface ia like expression and mixed lymphocyte reaction stimulating capacity of human leukemic myelo blasts implications for immuno therapy and prognosis. Acta Haematologica (Basel) 68(1): 3-13, 1982

Usefulness of the determination of serum and urinary muramidase activity in chronic and subacute myelo proliferative syndromes and in leukemia with a low percentage of myelo blasts part 2 application to various pathological cases. Clinica Chimica Acta 50(2): 265-273, 1974

Usefulness of the determination of serum and urinary muramidase activity in chronic and subacute myelo proliferative syndromes and in leukemia with a low percentage of myelo blasts part 1 semi automatic kinetic method. Clinica Chimica Acta 50(2): 257-264, 1974

Regulatory mechanisms connected with dna synthesis in fowl neopl leukemic myelo blasts iii enz deoxy thymidine phospho transferase activity of the supernatant fraction virus. Neoplasma (bratislava): 237-252, 1967

Fowl plague virus adapted to human epithelial tumor cells and human myelo blasts in vitro part 1 characteristics and replication in mono layer cultures. Archiv fuer die Gesamte Virusforschung 40(1-2): 137-151, 1973

Pre leukemic states part 1 definition and classification part 2 refractory anemia with an excess of myelo blasts in the bone marrow smoldering acute leukemia. Nouvelle Revue Francaise d'Hematologie 17(1/2): 33-55, 1976

Differentiation of leukemic myelo blasts. Yamamoto, Tadashi And Haruo Sugano (Ed ) Gann Monograph on Cancer Research, No 12 Experimental Leukemogenesis Symposium Tokyo, Japan Nov 13-14, 1970 Viii+321p Illus University Park Press: Baltimore, Md , U S A ; Tokyo, Japan 215-229, 1972